These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15454486)

  • 1. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
    Wang H; Cheng F; Cuenca A; Horna P; Zheng Z; Bhalla K; Sotomayor EM
    Blood; 2005 Feb; 105(3):1135-43. PubMed ID: 15454486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
    Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
    J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
    Sotomayor EM; Borrello I; Rattis FM; Cuenca AG; Abrams J; Staveley-O'Carroll K; Levitsky HI
    Blood; 2001 Aug; 98(4):1070-7. PubMed ID: 11493453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
    Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
    Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted aeroallergen access to airway mucosal dendritic cells in vivo limits allergen-specific CD4+ T cell proliferation during the induction of inhalation tolerance.
    Fear VS; Burchell JT; Lai SP; Wikstrom ME; Blank F; von Garnier C; Turner DJ; Sly PD; Holt PG; Strickland DS; Stumbles PA
    J Immunol; 2011 Nov; 187(9):4561-70. PubMed ID: 21930961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo.
    Schiering C; Guarnerio J; Basso V; Muzio L; Mondino A
    Cancer Res; 2010 Aug; 70(15):6161-70. PubMed ID: 20631073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Sep; 110(1):95-104. PubMed ID: 12941146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell tolerance to kappa light chain (L kappa): identification of a naturally processed self-C kappa-peptidic region by specific CD4+ T cell hybridomas obtained in L kappa-deficient mice.
    Faure M; Sanchez P; Cazenave PA; Rueff-Juy D
    Cell Immunol; 1997 Aug; 180(1):84-92. PubMed ID: 9316642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion, but not anergy, is involved in TGF-beta-treated antigen-presenting cell-induced tolerance.
    Alard P; Clark SL; Kosiewicz MM
    Int Immunol; 2003 Aug; 15(8):945-53. PubMed ID: 12882832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment.
    Riva G; Luppi M; Barozzi P; Quadrelli C; Basso S; Vallerini D; Zanetti E; Morselli M; Forghieri F; Maccaferri M; Volzone F; Del Giovane C; D'Amico R; Locatelli F; Torelli G; Comoli P; Potenza L
    Blood; 2010 Feb; 115(8):1512-8. PubMed ID: 20007806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells.
    Mascarell L; Lombardi V; Zimmer A; Louise A; Tourdot S; Van Overtvelt L; Moingeon P
    Clin Exp Allergy; 2009 Dec; 39(12):1910-9. PubMed ID: 19694757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness.
    Chung JB; Wells AD; Adler S; Jacob A; Turka LA; Monroe JG
    J Immunol; 2003 Aug; 171(4):1758-67. PubMed ID: 12902475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
    Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
    Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.
    Saint-Lu N; Tourdot S; Razafindratsita A; Mascarell L; Berjont N; Chabre H; Louise A; Van Overtvelt L; Moingeon P
    Allergy; 2009 Jul; 64(7):1003-13. PubMed ID: 19220212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.
    Taïeb J; Maruyama K; Borg C; Terme M; Zitvogel L
    Blood; 2004 Mar; 103(5):1966-7; author reply 1967. PubMed ID: 14976062
    [No Abstract]   [Full Text] [Related]  

  • 17. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
    Samoszuk M; Corwin MA
    Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor STI-571: the new wonder drug of cancer therapy.
    Haydon RC; Zhou L; He TC
    Cancer Biol Ther; 2004 Apr; 3(4):393-4. PubMed ID: 15004535
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.
    Keller AM; Schildknecht A; Xiao Y; van den Broek M; Borst J
    Immunity; 2008 Dec; 29(6):934-46. PubMed ID: 19062317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.